Last Price
14.34
Today's Change
+0.80 (5.90%)
Day's Change
13.63 - 15.24
Trading Volume
488,892
Overview
Market Cap
1 Billion
Shares Outstanding
127 Million
Avg Volume
438,576
Avg Price (50 Days)
16.69
Avg Price (200 Days)
20.02
PE Ratio
15.45
EPS
0.93
Earnings Announcement
30-Jan-2025
Previous Close
13.54
Open
13.65
Day's Range
13.63 - 15.24
Year Range
10.02 - 25.95
Trading Volume
491,751
Price Change Highlight
1 Day Change
6.13%
5 Day Change
5.66%
1 Month Change
-7.65%
3 Month Change
-27.93%
6 Month Change
-29.94%
Ytd Change
-42.10%
1 Year Change
28.53%
3 Year Change
600.98%
5 Year Change
568.37%
10 Year Change
680.98%
Max Change
151.66%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
2
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
